Skyscape Web Viewer : The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs : Main Index

View All
National Institute for Health and Care Excellence (NICE) antidepressants gabapentinoids Practical Options for Prescribing Gradually Tapering Doses The Neurobiology of Tapering benzodiazepines and z-drugs Mis-Diagnosis of Withdrawal Effects As Relapse The Context for Deprescribing
National Institute on Drug Abuse (NIDA) Physical Dependence vs Addiction in Use of Benzodiazepines and Z-Drugs Mis-Diagnosis of Withdrawal Effects As Relapse Recent Developments in the Understanding of Antidepressant Withdrawal
Neurobiology antidepressants Mis-Diagnosis of Withdrawal Effects As Relapse The Neurobiology of Tapering benzodiazepines and z-drugs Pathophysiology of Psychiatric Drug Withdrawal Symptoms
Neuromuscular disorders Discussing Deprescribing Benzodiazepines and Z-Drugs Variety of Withdrawal Symptoms from Benzodiazepines and Z-Drugs Clinical Aspects of Antidepressant Withdrawal Discussing Deprescribing Gabapentinoids
Neuropathic pain When and Why to Stop Gabapentinoids Tapering Gabapentinoids in Practice
Nitrazepam Switching to Longer-Acting Benzodiazepines to Taper Nitrazepam
Nocebo effects How Common, Severe and Long-Lasting are Withdrawal Symptoms from Antidepressants? Pathophysiology of Antidepressant Withdrawal Symptoms
Noradrenaline Clinical Aspects of Antidepressant Withdrawal Recent Developments in the Understanding of Antidepressant Withdrawal Hyperbolic Tapering of Antidepressants
Nutritional supplements Other Considerations in Tapering Benzodiazepines and Z-Drugs Other Considerations in Tapering Gabapentinoids
N-methyl-d-aspartate (NMDA)
Nortriptyline